During treatment, mutations in the IDH1 and ATRX genes are used to determine the grade and aggressiveness of a tumour, whereas the MGMT status is used to determine if treatment with DNA alkylating agents such as TMZ would be worthwhile. Here, IDH1 is linked to neoplasm.